MedTrace Logo

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 358

Last updated 2023-07-10

No results posted yet for this study

Summary

D1. Primary Objective:

1\. Determine the immunogenicity of FDA approved COVID-19 vaccination in patients with hematologic malignancies

D2. Secondary Objectives:

1. Assess the safety of FDA approved COVID-19 vaccination in patients with hematologic malignancies
2. Analyze the kinetics of immunogenic response over time after receipt of the COVID-19 vaccination
3. Compare the immunogenicity of different COVID-19 vaccinations that will be approved by the FDA
4. Analyze advanced flow immunophenotyping of innate and adaptive immune blood cells in all participants and correlate with response to vaccination

Conditions

  • Monoclonal B-Cell Lymphocytosis
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • B-cell Non Hodgkin Lymphoma
  • Hodgkin Lymphoma

Sponsors & Collaborators

Principal Investigators

  • Sameer Parikh, M.B.B.S. · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-28
Primary Completion
2022-07-13
Completion
2022-07-13

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04748185 on ClinicalTrials.gov